Fernando Bermejo
Overview
Explore the profile of Fernando Bermejo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
1371
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giordano A, Perez-Martinez I, Gisbert J, Ricart E, Martin-Arranz M, Mesonero F, et al.
Am J Gastroenterol
. 2025 Jan;
120(1):194-203.
PMID: 39745305
Introduction: Crohn's disease (CD) varies by location, potentially affecting therapy efficacy and surgery risk, although research on this topic is conflicting. This study aims to investigate the independent association between...
2.
Garcia M, Brenes Y, Vicuna M, Bermejo F, Sierra-Ausin M, Vicente R, et al.
Am J Gastroenterol
. 2024 Nov;
PMID: 39588977
Introduction: Real-world data on the effectiveness of upadacitinib for inflammatory bowel disease (IBD) are limited. To assess upadacitinib persistence, effectiveness, and safety in a real-world scenario. Methods: Retrospective multicenter study...
3.
Chaparro M, Hermida S, Acosta D, Fernandez-Clotet A, Barreiro-de Acosta M, Hernandez Martinez A, et al.
Aliment Pharmacol Ther
. 2024 Sep;
60(10):1325-1338.
PMID: 39287363
Background: Ustekinumab is approved for ulcerative colitis (UC). Aims: To assess the durability of ustekinumab in patients with UC and its short-term effectiveness, durability and tolerability in clinical practice. Methods:...
4.
Ferreiro-Iglesias R, Porto Silva S, Marin S, Casanova M, Manosa M, Gonzalez-Munoza C, et al.
Aliment Pharmacol Ther
. 2024 Jun;
60(5):604-612.
PMID: 38943230
Background: Ulcerative proctitis (UP) can have a milder, less aggressive course than left-sided colitis or extensive colitis. Therefore, immunosuppressants tend to be used less in patients with this condition. Evidence,...
5.
Casanova M, Caballol B, Garcia M, Mesonero F, Rubin de Celix C, Suarez-Alvarez P, et al.
Dig Liver Dis
. 2024 Jun;
56(11):1845-1853.
PMID: 38839456
Background: The efficacy of ustekinumab and vedolizumab for treating complex perianal fistula in Crohn's disease has been barely studied. We aimed to assess treatment persistence, clinical remission, and safety of...
6.
Gomez-Labrador C, Ricart E, Iborra M, Iglesias E, Martin-Arranz M, De Castro L, et al.
Pharmaceutics
. 2024 May;
16(5).
PMID: 38794292
Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life...
7.
Guerra I, Barros F, Chaparro M, Benitez J, Martin-Arranz M, de Francisco R, et al.
Dig Dis
. 2024 Mar;
42(3):257-264.
PMID: 38452742
Introduction: Risk factors for developing pancreatitis due to thiopurines in patients with inflammatory bowel disease (IBD) are not clearly identified. Our aim was to evaluate the predictive pharmacogenetic risk of...
8.
Casas Deza D, Polo Cuadro C, de Francisco R, Vela Gonzalez M, Bermejo F, Blanco I, et al.
J Crohns Colitis
. 2023 Nov;
18(4):578-588.
PMID: 37930823
Introduction: Intra-abdominal abscesses complicating Crohn's disease [CD] are a challenging situation. Their management, during hospitalisation and after resolution, is still unclear. Methods: Adult patients with CD complicated with intra-abdominal abscess....
9.
Aldars-Garcia L, Gil-Redondo R, Embade N, Riestra S, Rivero M, Gutierrez A, et al.
Inflamm Bowel Dis
. 2023 Aug;
30(2):167-182.
PMID: 37536268
Background And Aims: Inflammatory bowel disease (IBD) is a prevalent chronic noncurable disease associated with profound metabolic changes. The discovery of novel molecular indicators for unraveling IBD etiopathogenesis and the...
10.
Garcia M, Rivero M, Fernandez-Clotet A, de Francisco R, Sicilia B, Mesonero F, et al.
J Crohns Colitis
. 2023 Jul;
18(1):65-74.
PMID: 37522878
Background: Both vedolizumab and ustekinumab are approved for the management of Crohn's disease [CD]. Data on which one would be the most beneficial option when anti-tumour necrosis factor [anti-TNF] agents...